The specific name is also commonly pronounced , as though it were French, which from a prescriptive viewpoint is a "mispronunciation" but from a linguistically descriptive viewpoint cannot be described as erroneous because it is so widely used among health care professionals; it can be described as "the non-preferred variant" from the viewpoint of sticking most regularly to New Latin in binomial nomenclature, which is also a valid viewpoint, although New Latin specific names contain such a wide array of extra-Latin roots (including surnames and jocular references) that extra-Latin pronunciation is involved anyway (as seen, for example, with Ba humbugi, Spongiforma squarepantsii, and hundreds of others). Research
As of 2019, vaccine candidates providing immunity against C. difficile toxin A and C. difficile toxin B have advanced the most in clinical research, but do not prevent bacterial colonization. A vaccine candidate by Pfizer is in a phase 3 clinical trial that is estimated to be completed in September 2021 and a vaccine candidate by GlaxoSmithKline is in a phase 1 clinical trial that is estimated to be completed in July 2021. CDA-1 and CDB-1 (also known as MDX-066/MDX-1388 and MBL-CDA1/MBL-CDB1) is an investigational, monoclonal antibody combination co-developed by Medarex and Massachusetts Biologic Laboratories (MBL) to target and neutralize C. difficile toxins A and B, for the treatment of CDI. Merck & Co., Inc. gained worldwide rights to develop and commercialize CDA-1 and CDB-1 through an exclusive license agreement signed in April 2009. It is intended as an add-on therapy to one of the existing antibiotics to treat CDI.
Symptoms
Dust mite allergy symptoms include:

Cough
Facial pressure and pain
Itchy, red or watery eyes
Itchy nose, roof of the mouth or throat
Nasal congestion
Postnasal drip
Runny nose, sneezing
Swollen, blue-colored skin under the eyesIf the dust mite allergy contributes to asthma:

Audible whistling or wheezing sound when exhaling
Bouts of coughing or wheezing that are worsened by a respiratory virus such as a cold or the flu
Chest tightness or pain
Difficulty breathing
Trouble sleeping caused by shortness of breath, coughing or wheezing

Cross-reactivity to shellfish allergy
Tropomyosin, the major allergen in dust mites, is also responsible for shellfish allergy. Exposure to inhaled tropomyosins from dust mites is thought to be the primary sensitizer for shellfish allergy, an example of inhalant-to-food cross-reactivity. Epidemiological surveys have confirmed correlation between shellfish and dust mite sensitizations. An additional confirmation was seen in Orthodox Jews with no history of shellfish consumption, in that skin tests confirming dust mite allergy were also positive for shellfish tropomyosin. In addition to tropomyosin, the proteins arginine kinase and hemocyanin seem to have a role in cross-reactivity to dust mites. Prevention
House dust mites are present indoors wherever humans live. Positive tests for dust mite allergies are extremely common among people with asthma. Dust mites are microscopic arachnids whose primary food is dead human skin cells, but they do not live on living people. They and their feces and other allergens that they produce are major constituents of house dust, but because they are so heavy they are not suspended for long in the air.